Marksans Pharma's subsidiary Time-Cap Laboratories has successfully received an establishment inspection report (EIR) from the US Food and Drug Administration following a comprehensive current Good Manufacturing Practices inspection at its New York facility. The regulatory milestone represents a positive outcome for the pharmaceutical company's US operations.
FDA Inspection Details
The US FDA conducted a thorough cGMP inspection at Time-Cap Laboratories' manufacturing facility located on Michael Avenue in Farmingdale, New York, between April 16-24, 2025. Following the inspection, the regulatory agency issued only one inspectional observation in Form 483, with notably no data integrity observations identified during the review process.
The receipt of the EIR indicates that the FDA has completed its review of the facility and any corrective actions taken in response to the inspection findings. This regulatory clearance is crucial for maintaining the facility's operational status and continued manufacturing capabilities.
Company Operations and Portfolio
Marksans Pharma operates as a global pharmaceutical company engaged in research, manufacturing, and marketing of generic pharmaceutical formulations. The company maintains a diversified manufacturing footprint with facilities across India, USA, and UK, all approved by leading regulatory agencies including the USFDA, UKMHRA, and Australian TGA.
The company's product portfolio spans major therapeutic segments including cardiovascular (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterological, and antiallergic medications. These products are marketed globally, positioning Marksans Pharma as a significant player in the international generic pharmaceuticals market.
Financial Performance
Marksans Pharma demonstrated robust financial growth in the fourth quarter of fiscal year 2025, reporting a 15.7% increase in consolidated net profit to Rs 90.55 crore compared to the same period in the previous year. The company's revenue from operations grew by 26.5% to Rs 708.46 crore in Q4 FY25, reflecting strong operational performance across its business segments.
The successful FDA inspection outcome and EIR receipt for the New York facility supports the company's continued growth trajectory and regulatory compliance across its global manufacturing network.
